Clinical Trials in Pittsburgh

Showing 9141-9160 of 16,007 trials

Dose Finding and Safety of Oral LDE225 in Patients With Advanced Solid Tumors

NCT00880308

This first-in-human dose-escalation study is to characterize the safety, tolerability, pharmacokinetics and pharmacodynamics of LDE225 given orally on a daily dosing schedule in patients with advanced solid tumors.

Advanced Solid Tumor CancersMedulloblastomaBasal Cell Carcinoma

Novartis Pharmaceuticals103 participantsStarted Mar 2009

Pittsburgh, Pennsylvania, United States • San Antonio, Texas, United States • Barcelona, Catalonia, Spain +2 more locations

TERMINATEDPhase 2< 1 mile

Safety and Efficacy of QAX576 in Patients With Idiopathic Pulmonary Fibrosis (IPF)

NCT01266135

This study is designed to evaluate the safety, tolerability, pharmacokinetics and efficacy of QAX576 in patients with idiopathic pulmonary fibrosis.

Idiopathic Pulmonary Fibrosis

Novartis Pharmaceuticals40 participantsStarted Dec 2010

Gainesville, Florida, United States • Orlando, Florida, United States • Boston, Massachusetts, United States +7 more locations

COMPLETEDPhase 277 miles

A Study to Evaluate the Efficacy and Safety of MIN-117 in Adult Patients With Major Depressive Disorder

NCT03446846

MIN-117C03 is a 6-week, 3-arm, randomized, double-blind, placebo controlled study to investigate the safety and efficacy of MIN-117 in male and female patients with Major Depressive Disorder, aged 18 to 65 years. Approximately 324 patients were to be randomly assigned to 1 of 3 treatment arms, including placebo, 2.5 mg MIN-117, or 5.0 mg MIN-117, in a 2:1:1 ratio.

Major Depressive Disorder

Minerva Neurosciences360 participantsStarted Mar 2018

Little Rock, Arkansas, United States • Garden Grove, California, United States • Torrance, California, United States +44 more locations

Dose Finding and Safety of Oral LDE225 in Patients With Advanced Solid Tumors

Safety and Efficacy of QAX576 in Patients With Idiopathic Pulmonary Fibrosis (IPF)

A Study to Evaluate the Efficacy and Safety of MIN-117 in Adult Patients With Major Depressive Disorder

Find Trials by Condition in Pittsburgh

A Study to Assess the Safety and Efficacy of Lacosamide Versus Placebo (a Pill Without Active Medication) in Patients With Idiopathic Generalised Epilepsy Who Are Already Taking Anti-epileptic Medications

In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol®

Efficacy and Safety of Patupilone in Men (≥18 Years) With Metastatic Hormone Refractory Prostate Cancer

Safety and Efficacy Study of Oral Fosfomycin Versus Oral Levofloxacin to Treat Complicated Urinary Syndromes (FOCUS)

A Phase I, Multi-center, Open Label, Drug-drug Interaction Study to Assess the Effect of Ceritinib on the Pharmacokinetics of Warfarin and Midazolam in Patients With ALK-positive Advanced Tumors

Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)

A Biobehavioral Intervention for Young Men With Testicular Cancer

A Multi-center Study to Assess the Effects of BYM338 on Skeletal Muscle in Sarcopenic Adults

Efficacy, Safety and Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis

Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2+ or ER+ Locally Advanced or Metastatic Breast Cancer Patients

LFF269 Compared to Placebo After Treatment in Subjects With Essential Hypertension

A Trial l of Panobinostat Given in Combination With Trastuzumab and Paclitaxel in Adult Female Patients With HER2 Positive Metastatic Breast Cancer

Adaptive-design Dose Finding Study to Assess the Antiviral Efficacy and Safety of NIM811 Administered in Combination With Standard of Care (SOC) in Relapsed Hepatitis C Virus 1 (HCV-1) Infected Patients

Effect of Hepatic Impairment on LDE225..

PCA062 in pCAD-positive Tumors.

A Phase I-Ib/II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 Alone and in Combination With Bortezomib, With or Without Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma.

Pharmacokinetics of rFVIIIFc at Two Vial Strengths